All In Biotech

Drug Trial Radar · NCT07641634

A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

A Two-part, Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study of PRO-203 in Healthy Adult Volunteers Followed by an Open-label, Single-ascending-dose With Priming Study of PRO-203 in Participants With Systemic Sclerosis

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Oct 27, 2025

Primary completion

Jan 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Prolium Bioscience, IncIndustry
Sponsor type
Industry
First posted
Jun 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A two-part study of PRO-203 administered subcutaneously in healthy adult volunteers and participants with Systemic Sclerosis (SSc).

Conditions

  • Healthy Volunteers
  • Systemic Sclerosis (SSc)
  • Scleroderma, Systemic
  • Scleroderma

Interventions

  • PRO-203Drug

    PRO-203 administered as escalating single dose in healthy participants or as a single cycle in participants with systemic sclerosis.

  • PlaceboOther

    Matching placebo comparator for Part 1 participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events and Laboratory Abnormalities [Safety and Tolerability]Time frame: 13 weeks (Part 1) / 49 weeks (Part 2)

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Nucleus Network

    Melbourne, Victoria, Australia · Completed

  • Peking University Third Hospital

    Beijing, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Recruiting

  • The Third Affiliated Hospital of Sun Yat-Sen University

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Henan, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, China · Recruiting

  • Pingxiang People's Hospital

    Pingxiang, China · Recruiting

  • Hospital Angeles Chihuahua

    Chihuahua City, Mexico · Recruiting

  • Unidad Médica para la Salud Integral (UMSI)

    San Nicolás de los Garza, Mexico · Recruiting

  • Kyung Hee University Hospital

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.